Marc S. Sabatine

Marc S. Sabatine

Cardiology

55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 491 publications

Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial.

Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial.

Journal: Circulation

Published: August 31, 2026

Effect of In-Hospital Initiation of Dapagliflozin on Decongestion in Patients Hospitalized for Heart Failure: An Analysis of the DAPA ACT HF-TIMI 68 Trial.

Effect of In-Hospital Initiation of Dapagliflozin on Decongestion in Patients Hospitalized for Heart Failure: An Analysis of the DAPA ACT HF-TIMI 68 Trial.

Journal: JACC. Heart failure

Published: July 27, 2026

Evolocumab to Reduce Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis-Reply.

Evolocumab to Reduce Cardiovascular Events in Patients With Diabetes Without Known Significant Atherosclerosis-Reply.

Journal: JAMA

Published: July 23, 2026

Development and Validation of a Simplified Martin-Hopkins LDL-C Equation Using Machine Learning.

Development and Validation of a Simplified Martin-Hopkins LDL-C Equation Using Machine Learning.

Journal: JAMA cardiology

Published: July 15, 2026

Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study.

Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study.

Journal: Journal of the American College of Cardiology

Published: July 07, 2026

Evolocumab and risk of first myocardial infarction: the VESALIUS-CV trial.

Evolocumab and risk of first myocardial infarction: the VESALIUS-CV trial.

Journal: European heart journal

Published: July 07, 2026

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

Journal: Journal of lipid research

Published: June 13, 2026

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial.

Journal: Circulation

Published: May 25, 2026

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior Myocardial Infarction: Results From the VESALIUS-CV Trial.

Journal: Circulation

Published: May 19, 2026

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

Journal: Circulation

Published: May 19, 2026

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Journal: Research square

Published: May 18, 2026

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Rare coding variant architecture and gene discovery from 130,000 sequenced cases of atrial fibrillation.

Journal: Research square

Published: May 18, 2026

Showing 1-12 of 491

Last Updated: 09/26/2026